CN Patent

CN107384932B — 抗人cd20人源化单克隆抗体mil62、其制备方法及用途

Assigned to Beijing Mabworks Biotech Co Ltd · Expires 2020-10-20 · 6y expired

What this patent protects

本发明涉及一种抗人CD20人源化单克隆抗体，以及编码所述抗人CD20人源化单克隆抗体的核酸分子。本发明还涉及所述抗人CD20人源化单克隆抗体的制备方法，所述核酸分子用于制备所述人源化单克隆抗体的用途，以及所述人源化单克隆抗体用于制备抗肿瘤、自身免疫疾病及炎症的药物的用途。与现有的抗人CD20人源化单克隆抗体Rituximab和GA101相比，本发明的抗人CD20人源化单克隆抗体具有增强的ADCC活性。

USPTO Abstract

本发明涉及一种抗人CD20人源化单克隆抗体，以及编码所述抗人CD20人源化单克隆抗体的核酸分子。本发明还涉及所述抗人CD20人源化单克隆抗体的制备方法，所述核酸分子用于制备所述人源化单克隆抗体的用途，以及所述人源化单克隆抗体用于制备抗肿瘤、自身免疫疾病及炎症的药物的用途。与现有的抗人CD20人源化单克隆抗体Rituximab和GA101相比，本发明的抗人CD20人源化单克隆抗体具有增强的ADCC活性。

Drugs covered by this patent

Patent Metadata

Patent number
CN107384932B
Jurisdiction
CN
Classification
—
Expires
2020-10-20
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Mabworks Biotech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.